Why "personalized" compounded tirzepatide claims failed a Lilly ad challenge

The advertising language that sells compounded tirzepatide was tested this week and mostly lost. On November 4, the National Advertising Division recommended that Good Life Meds stop describing its compounded Tirzepatide+ product as "personalized" or "tailored to meet individual patient needs," and stop claiming the finished product supports weight loss, lifts energy, improves blood sugar control and preserves lean muscle.[1]

Reader offer · IQON Labs

Buy 1, Get 1 20% Off

Pick any two research compounds. Take 20% off the lower priced one.

20% OFF

Applied automatically at checkout, no code needed

Claim my 20% off →

In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.

Reported analysis of the November 4, 2026 advertising decision, the panel's published procedures and the advertiser's public materials. The panel made no finding that any law was violated, and no medical claim is made here.

What the panel decided, and what it would not accept

Good Life sells compounded tirzepatide through a telehealth platform as Tirzepatide+, a formula that pairs the drug with additive ingredients. Lilly, which makes the approved tirzepatide medicines Mounjaro and Zepbound, challenged the advertising on efficacy, safety, FDA status and personalization grounds.[1]

The company brought a substantial evidence file: published tirzepatide trials, separate literature on the additives, a Gallup survey and retrospective cohort studies. The panel read it and found the pieces did not connect to the product being sold. Most of the tirzepatide literature studied Lilly's approved medicines rather than a compounded formula with extra ingredients. The survey and the cohort studies did not examine Tirzepatide+ at all. Nothing in the record tested the safety of combining tirzepatide with the additives.[1]

The panel also rejected an argument that recurs across the compounded market: that FDA's decision to permit compounding during drug shortages substantiated the claims. Permission to compound says nothing about whether a finished product delivers the benefits advertised, and the panel treated the two questions as separate.[1]

Why "personalized" did not survive

The second half of the decision matters for anyone who reads telehealth advertising closely. Good Life described the product as "a personalized medication... tailored to meet individual patient needs" and as "compounded for your unique needs." The panel accepted that a prescriber can choose among available formulations and doses, and can adjust a patient's plan over time. It concluded that this is not the same as a product being individually created or formulated for that patient, and that the advertising overstated what the process involves.[1]

The distinction is narrow and practical. A pharmacy holding stock of a compounded formula and dispensing it under a prescription is not formulating to a person. The recommendation was to discontinue the words "personalized," "custom formulated," "tailored to meet individual patient needs" and "compounded for your unique needs."[1]

A pattern of challenges, and one that reached the merits

This is not an isolated dispute. On June 3, 2025, the same panel published two other decisions in challenges Lilly brought over compounded tirzepatide advertising. Striker Pharmacy permanently discontinued the claims at issue, and Begin Anew MedSpa did the same, so in neither case did the panel reach the merits.[2][3] The Begin Anew file included a claim that its tirzepatide product was FDA approved and a promise of "fast and extreme" weight loss without lifestyle changes.[3]

That pattern shapes what the public record can teach. When an advertiser withdraws during an inquiry, the published summary records the withdrawal and little else. Good Life defended the claims instead, and lost the health benefit and personalization arguments.[1] That makes this the most detailed public account so far of how an evidence-based reviewer treats compounded tirzepatide marketing in this run of cases.

What the panel cannot do

The National Advertising Division is a self-regulatory body, not a court. Its published procedures state that a decision "does not constitute a finding that any law has been violated" and that an advertiser's voluntary participation "is not an admission."[4] It cannot fine a company or pull a product from sale. Its influence rests on participation and publicity, and its decisions can be appealed to the National Advertising Review Board, the appellate body for the same system.[5]

That limit explains the sequence readers will see in practice. Good Life said it disagrees with "many aspects" of the decision and that it will comply with the recommendations.[1] Compliance is a company action, not an enforcement event, and the timing is set by the advertiser.

The claims were still online the next morning

On November 5, the product page for Tirzepatide+ still described it as "a personalized medication sourced from US-based and licensed pharmacies, tailored to meet individual patient needs."[6] That is the sentence the panel asked the company to stop using, still published a day after the decision.

The gap is ordinary in self-regulation. A recommendation takes effect when the advertiser acts, and the panel publishes a summary rather than monitoring websites. For readers, the practical consequence is that advertising language describes an intention to sell, not a verified property of the product. FDA's own consumer guidance is blunt on the underlying point: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed.[7]

What the decision changes for sellers and buyers

For sellers, the lesson is about evidence fit rather than evidence volume. Studies of an approved drug support claims about that drug. They do not automatically support claims about a compounded version with added ingredients, and they do not support outcomes nobody measured in the finished product. Two of the four categories Lilly challenged, safety and FDA status, were resolved by voluntary discontinuance rather than adjudication, which leaves those questions open for the next case.[1]

For buyers, "personalized" turns out to be marketing language with no standard behind it. A prescription written for one person is not the same as a medicine manufactured for one person, and the panel said so directly.[1] The same test applies to the word on any compounded product page, including ones that have never been challenged.

The next document to watch is an appeal to the National Advertising Review Board, which would put the panel's reasoning in front of a five-member industry panel.[5] Absent one, the record now holds a detailed public test of what compounded tirzepatide advertising must prove, and a company that has promised to change its words while disputing the conclusion.

Frequently asked questions

Is a National Advertising Division decision legally binding?

No. The division is part of the advertising industry's voluntary self-regulation system, and its procedures state that a decision does not constitute a finding that any law has been violated. It cannot fine a company or remove a product from sale. Decisions can be appealed to the National Advertising Review Board, and compliance depends on the advertiser.

[4] [5]

Did Good Life Meds admit its claims were false?

No. The company said it disagrees with many aspects of the decision and that it will comply with the recommendations. During the inquiry it had already permanently discontinued certain claims about clinical results, benefits, ingredients, safety and sourcing, which the panel treats as though it had recommended they stop.

[1]

Does this decision make compounded tirzepatide illegal?

No. The decision concerns advertising claims, not the legality of compounding, and the panel made no finding that any law was violated. Separately, FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before marketing.

[4] [7]